Federal Register of Legislation - Australian Government

Primary content

PB 93 of 2019 Determinations/Health as made
This instrument amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (No. PB 119 of 2008) to provide for additions, deletions and changes to drugs and forms in Schedules 1 to 5.
Administered by: Health
Registered 28 Nov 2019
Tabling HistoryDate
Tabled HR02-Dec-2019
Tabled Senate02-Dec-2019
To be repealed 24 Mar 2020
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 93 of 2019

 

National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No. 9)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

 

Dated   27th November 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No. 9).

(2)          This Instrument may also be cited as PB 93 of 2019.

2          Commencement

This Instrument commences on 1 December 2019.

3          Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

 

 

 

 

 

 

 

 

 

                     

                     


Schedule 1     Amendments

[1]        Schedule 4, entry for Aciclovir

omit:

 

Eye ointment 30 mg per g, 4.5 g

 

 

[2]        Schedule 4, entry for Brinzolamide with brimonidine

omit from the column headed “Form (strength, type, size, etc.)”: Eye drops 10 mg brinzolamide and 2 mg brimonidine tartarate per mL, 5 mL
substitute: Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL

[3]        Schedule 4, omit entry for Buprenorphine

[4]        Schedule 4, entry for Carmellose

insert as first entry:

 

Eye drops containing carmellose sodium 5 mg per mL, 10 mL

[5]        Schedule 4, entry for Clobetasol

omit from the column headed “Form (strength, type, size, etc.)”: Shampoo containing clobetasol propionate 500 micrograms per mL, 125 mL
substitute: Shampoo containing clobetasol propionate 500 microgram per mL, 125 mL

[6]        Schedule 4, omit entry for Fluticasone

[7]        Schedule 4, after entry for Fluticasone furoate with vilanterol

insert:

Fluticasone propionate

Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC‑free formulation)

 

Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation)

 

Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation)

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses

[8]        Schedule 4, entry for Fluticasone with formoterol

omit from the column headed “Listed Drug”: Fluticasone with formoterol      substitute: Fluticasone propionate with formoterol

[9]        Schedule 4, entry for Fluticasone with Salmeterol

omit from the column headed “Listed Drug”: Fluticasone with Salmeterol      substitute: Fluticasone propionate with salmeterol

[10]      Schedule 4, entry for Hypromellose

insert as first entry:

 

0.3% w/v eye drops, 10 mL (preservative free)

[11]      Schedule 4, after entry for Levetiracetam

insert:

Lumacaftor with ivacaftor

Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg

 

Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg

[12]      Schedule 4, entry for Triamcinolone with Neomycin, Gramicidin and Nystatin

             omit from the column headed “Form (strength, type, size, etc.)”: Ear drops containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 7.5 mL       substitute: Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per mL, 7.5 mL